Osmotica Pharmaceuticals (OSMT) IPO Opens 29% Higher

Today's IPO for Osmotica Pharmaceuticals (NASDAQ: OSMT) opened for trading at $9 after pricing 6,650,000 ordinary shares at a public offering price of $7.

Jefferies, Barclays, RBC Capital Markets and Wells Fargo Securities acted as joint lead book-running managers for the offering.

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. Our diversified product portfolio in the specialty neurology and women's health space, together with our non-promoted complex formulations of generic drugs, form the foundation of our unwavering commitment to improve patients' lives.

Osmotica has a late‑stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: Arbaclofen ER (extended‑release) tablets for muscle spasticity in multiple sclerosis patients and RVL‑1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.

You May Also Be Interested In

• Trans-lux Corporation (TLX) Files for Proposed US IPO
• Raytech Holding (RAY) Opens At $5.05, IPO Priced At $4
• Jefferies Upgrades DuPont Inc. (DOW) to Buy